ClinicalTrials.gg
Not yet recruitingNCT07812532Updated Sep 10, 2026

Effect of Gamified Sun Protection Education Provided to Chemotherapy Patients

An interventional study of Gamified education in Chemotherapy, Sun Protection and Self Efficacy, sponsored by Lokman Hekim University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Lokman Hekim University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Chemotherapy may cause photosensitivity and other skin reactions that can negatively affect patients' comfort, quality of life, and adherence to treatment. Appropriate sun protection behaviors are therefore important for patients receiving chemotherapy.

This randomized controlled trial aims to evaluate the effect of gamified sun protection education on sun protection self-efficacy and sun protection behaviors in patients receiving chemotherapy.

A total of 54 patients will be randomly assigned to two groups, with 27 participants in each group. Participants in the intervention group will receive gamified sun protection education, while participants in the control group will receive usual care. The educational intervention will be delivered over a two-week period.

Sun protection self-efficacy and sun protection behaviors will be assessed at baseline and after completion of the two-week intervention.

02

Conditions studied

  • Chemotherapy
  • Sun Protection
  • Self Efficacy
  • Oncology Patients
  • Education
  • Gamification in Health Education

Browse trials for

Keywords

  • Sun protection
  • Oncology patients
  • Education
  • gamification
  • Chemotherapy
  • Gamification in health education
  • self efficiency
03

In context

Health Education

481 studies on the registry are indexed under Health Education; 110 are open to participants now.

This study's planned enrollment of 54 is below the median of 132 across 450 interventional studies indexed under Health Education.

Browse Health Education studies →

Lead sponsor

Lokman Hekim University is the lead sponsor of 43 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently receiving chemotherapy
  • Aged 18 years or older
  • No major mental disorder that may interfere with participation in the study
  • No major visual, hearing, or communication impairment that may interfere with participation in the study
  • Able to read and write in Turkish
  • Willing to participate voluntarily in the study
  • Able to use mobile applications and a smartphone

Exclusion criteria

Exclusion Criteria:

-Receiving radiotherapy concurrently with chemotherapy

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Behavioral: Gamified education

  • No intervention
    control group

Interventions

  • BehavioralGamified education

    Gamified education

06

What researchers measure

Primary outcomes

  1. Change in Sun Protection Self-Efficacy Scale Total Score

    Sun protection self-efficacy will be assessed using the Sun Protection Self-Efficacy Scale. The outcome will be the change in the total scale score from baseline to the end of the 2-week intervention. Higher scores indicate greater self-efficacy regarding sun protection behaviors.

    Time frame: Baseline and immediately after completion of the 2-week intervention

Secondary outcomes

  1. Change in Sun Protection Behavior Scale Total Score

    Sun protection behaviors will be assessed using the Sun Protection Behavior Scale. The outcome will be the change in the total scale score from baseline to the end of the 2-week intervention. Higher scores indicate greater engagement in sun protection behaviors.

    Time frame: Baseline and immediately after completion of the 2-week intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) are not planned to be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.

Of 292 non-industry interventional studies with no phase under Health Education, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 2 months is below that.

Counting every sponsor, half of 293 studies reached it within 11 months; a quarter within 3 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Sep 10, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07812532
Lead sponsor
Lokman Hekim University
Collaborators
The Scientific and Technological Research Council of Turkey
Responsible party
Esra Turker (Associate Professor, Lokman Hekim University) — Principal investigator
First posted
Sep 10, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 10, 2026

Study contacts

Esra Türker, PhD
Contact
esra.turker@lokmanhekim.edu.tr
+905074521224
Esra Türker
principal investigator · Lokman Hekim University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion